CASC8 and pancreatic adenocarcinoma: Here, we, for the first time, establish an ARRSM based on CASC8, AC015660.1, Z97832.2 and PAN3-AS1, which not only offer more promising targets, but also better assess tumour vascularization status and prognosis for PAAD patients.